Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome

the Long-term Effects of High-doSe pitavaStatin on Diabetogenicity in Comparison With Atorvastatin in Patients With Metabolic Syndrome (LESS-DM) Randomized Clinical Trial

This purpose of this study is to evaluate effect of high-dose Pitavastatin on glucose control in patients with metabolic syndrome.

Inclusion Criteria:

• Patients diagnosed as metabolic syndrome according to National cholesterol Education Program criteria
• Patients with hypercholesterolemia who required to start statin therapy

Exclusion Criteria:

• overt diabetes
• acute coronary syndrome within 2 months
• acute cerebrovascular event within 2 months
• recent treatment of statin within 1month
• recent diagnosed neoplasm
• recent diagnosed liver disease
• chronic kidney disease
• patients with myopathy
• pregnant women, nursing mothers, women with possibility of pregnant
• patients being adminstered cyclosporine
• patients with genetic disease such as galactose intolerance, lactose intolerance, glucose-galactose malabsorption
• patients with treatment cyclosporin